Zydus Lifesciences Gains USFDA Approval for New Diabetes Drug Zituvimet XR

Zydus Lifesciences has received approval from the US FDA for Zituvimet XR, a diabetes medication combining sitagliptin and metformin hydrochloride. The drug aims to improve glycemic control in adults with type 2 diabetes. Zituvimet XR will be produced in Ahmedabad SEZ and taps into the $9.5 billion US market for oral diabetes medications.

Zydus Lifesciences announced that it has received approval from the US FDA for its new diabetes drug Zituvimet XR.

The extended-release tablets, combining sitagliptin and metformin hydrochloride, are intended to improve glycemic control in adults with type 2 diabetes, alongside diet and exercise.

Zituvimet XR will be manufactured at the company's Ahmedabad SEZ facility. According to IQVIA, the US market for DPP-IV inhibitors and their combinations is valued at $9.5 billion. Shares of Zydus Lifesciences were down 2.04% at Rs 1,161.10 on the BSE.

(With inputs from agencies.)